Figure 7.

Estimated benefit and harm due to genetically lower non-high-density lipoprotein-cholesterol and genetically higher high-density lipoprotein-cholesterol due to inhibition of cholesteryl ester transfer protein. Based on individuals in the Copenhagen General Population Study. Lower non-high-density lipoprotein-cholesterol by 0.44 mmol/L (17 mg/dL) and higher high-density lipoprotein-cholesterol by 1.12 mmol/L (43 mg/dL) correspond to the changes observed through anacetrapib treatment compared with placebo in the REVEAL trial.⁹ AMD, age-related macular degeneration; HDL, high-density lipoprotein; Δ=difference. Adapted from Nordestgaard et al.¹⁴⁴